Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome
Daniel Wiseman, John Lin, Jean‐Pierre Routy, Gordan Samoukovic
Abstract
Haemophagocytic lymphohistiocytosis (HLH) causing multiorgan failure has been reported as an acute clinical presentation of COVID-19. However, the literature surrounding HLH in the context of a postacute COVID-19 syndrome is limited. This report presents a case of a life-threatening HLH occurring 6 weeks after a pauci-symptomatic COVID-19 infection in a previously healthy adult. A bone marrow aspirate confirmed the HLH and the patient was successfully treated with dexamethasone and etoposide. To our knowledge, this is the first case of HLH occurring as a postacute COVID-19 syndrome following a pauci-symptomatic initial infection.
Topics & Concepts
Hemophagocytic lymphohistiocytosisCoronavirus disease 2019 (COVID-19)MedicineEtoposideContext (archaeology)DexamethasoneSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmunologyPathologyInternal medicineChemotherapyDiseaseBiologyOutbreakInfectious disease (medical specialty)PaleontologyAutoimmune and Inflammatory Disorders ResearchKawasaki Disease and Coronary ComplicationsImmune Cell Function and Interaction